Építés alatt – nem éles oldal
Belépés

NCT06735612Leállítva

Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 14.

Megadott ok: After extending RECODE recruitment for a second year due to low enrolment, the Sponsor closed it on 1 May 2026, after the second RSV season, with 716/892 patients. Further non-RSV recruitment offered limited value; there were no safety concerns.

Rövid összefoglaló (regiszter, angolul)

The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is: * What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season? * Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and/or death in patients with COPD exacerbations? Researchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death. Participants will: * Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms. * Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and/or oral corticosteroids if prescribed during hospitalization. * Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation. * Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period. * Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.

Állapot (regiszter)
Leállítva
Vizsgálattípus
Megfigyeléses
Résztvevők száma
716 (tényleges)
Első benyújtás
2024. dec. 11.
Kezdés
2024. dec. 16.
Elsődleges befejezés
2026. máj. 1.
Fő szponzor
Fundacio Privada Mon Clinic Barcelona
NCT-szám
NCT06735612

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Previous RSV vaccination (other vaccines will be allowed and recorded)

Más betegség

  • Active cancer (or any other disease) that may alter the immune status of the patient
  • Neurologic disorders that incapacitate the participation of the patient

Egyéb

  • No signing of the informed consent

Kiket keres a vizsgálat

  • Female or male
  • ≥50 years of age
  • Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: "in a patient with COPD, an exacerbation is an event characterized by dyspnea and/or cough and sputum that worsen over <14 d, which may be accompanied by tachypnoea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways"

Életkor a regiszterben: 50 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Hospital Clinic de BarcelonaBarcelonaSpanyolországIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Kapcsolódó publikációk

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.